These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 22917519)

  • 1. Inhibitor scaffold for the histone lysine demethylase KDM4C (JMJD2C).
    Leurs U; Clausen RP; Kristensen JL; Lohse B
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5811-3. PubMed ID: 22917519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors.
    Korczynska M; Le DD; Younger N; Gregori-Puigjané E; Tumber A; Krojer T; Velupillai S; Gileadi C; Nowak RP; Iwasa E; Pollock SB; Ortiz Torres I; Oppermann U; Shoichet BK; Fujimori DG
    J Med Chem; 2016 Feb; 59(4):1580-98. PubMed ID: 26699912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme kinetic studies of histone demethylases KDM4C and KDM6A: towards understanding selectivity of inhibitors targeting oncogenic histone demethylases.
    Kristensen JB; Nielsen AL; Jørgensen L; Kristensen LH; Helgstrand C; Juknaite L; Kristensen JL; Kastrup JS; Clausen RP; Olsen L; Gajhede M
    FEBS Lett; 2011 Jun; 585(12):1951-6. PubMed ID: 21575637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives.
    Westaway SM; Preston AG; Barker MD; Brown F; Brown JA; Campbell M; Chung CW; Diallo H; Douault C; Drewes G; Eagle R; Gordon L; Haslam C; Hayhow TG; Humphreys PG; Joberty G; Katso R; Kruidenier L; Leveridge M; Liddle J; Mosley J; Muelbaier M; Randle R; Rioja I; Rueger A; Seal GA; Sheppard RJ; Singh O; Taylor J; Thomas P; Thomson D; Wilson DM; Lee K; Prinjha RK
    J Med Chem; 2016 Feb; 59(4):1357-69. PubMed ID: 26771107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives.
    Westaway SM; Preston AG; Barker MD; Brown F; Brown JA; Campbell M; Chung CW; Drewes G; Eagle R; Garton N; Gordon L; Haslam C; Hayhow TG; Humphreys PG; Joberty G; Katso R; Kruidenier L; Leveridge M; Pemberton M; Rioja I; Seal GA; Shipley T; Singh O; Suckling CJ; Taylor J; Thomas P; Wilson DM; Lee K; Prinjha RK
    J Med Chem; 2016 Feb; 59(4):1370-87. PubMed ID: 26771203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational design, synthesis and biological profiling of new KDM4C inhibitors.
    Letfus V; Jelić D; Bokulić A; Petrinić Grba A; Koštrun S
    Bioorg Med Chem; 2020 Jan; 28(1):115128. PubMed ID: 31784197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecule KDM4s inhibitors as anti-cancer agents.
    Lin H; Li Q; Li Q; Zhu J; Gu K; Jiang X; Hu Q; Feng F; Qu W; Chen Y; Sun H
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):777-793. PubMed ID: 29651880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substrate- and cofactor-independent inhibition of histone demethylase KDM4C.
    Leurs U; Lohse B; Rand KD; Ming S; Riise ES; Cole PA; Kristensen JL; Clausen RP
    ACS Chem Biol; 2014 Sep; 9(9):2131-8. PubMed ID: 25014588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and Characterisation of Substrate-Based Peptides as Inhibitors of Histone Demethylase KDM4C.
    Nielsen SD; Leurs U; Bergner M; Barris SA; Devkota K; Meyer K; Iaria D; McCaughan J; Lohse B; Kristensen JL; Clausen RP
    Protein Pept Lett; 2016; 23(9):772-6. PubMed ID: 27295953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.
    Rotili D; Tomassi S; Conte M; Benedetti R; Tortorici M; Ciossani G; Valente S; Marrocco B; Labella D; Novellino E; Mattevi A; Altucci L; Tumber A; Yapp C; King ON; Hopkinson RJ; Kawamura A; Schofield CJ; Mai A
    J Med Chem; 2014 Jan; 57(1):42-55. PubMed ID: 24325601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-throughput TR-FRET assays for identifying inhibitors of LSD1 and JMJD2C histone lysine demethylases.
    Yu V; Fisch T; Long AM; Tang J; Lee JH; Hierl M; Chen H; Yakowec P; Schwandner R; Emkey R
    J Biomol Screen; 2012 Jan; 17(1):27-38. PubMed ID: 21859682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review.
    Chin YW; Han SY
    Expert Opin Ther Pat; 2015 Feb; 25(2):135-44. PubMed ID: 25468267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies of H3K4me3 demethylation by KDM5B/Jarid1B/PLU1 reveals strong substrate recognition in vitro and identifies 2,4-pyridine-dicarboxylic acid as an in vitro and in cell inhibitor.
    Kristensen LH; Nielsen AL; Helgstrand C; Lees M; Cloos P; Kastrup JS; Helin K; Olsen L; Gajhede M
    FEBS J; 2012 Jun; 279(11):1905-14. PubMed ID: 22420752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compounds and methods for inhibiting histone demethylases: a patent evaluation of US20160102096A1.
    Thaler F; Mercurio C
    Expert Opin Ther Pat; 2016 Dec; 26(12):1367-1370. PubMed ID: 27730846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tetrazolylhydrazides as Selective Fragment-Like Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A.
    Rüger N; Roatsch M; Emmrich T; Franz H; Schüle R; Jung M; Link A
    ChemMedChem; 2015 Nov; 10(11):1875-83. PubMed ID: 26337137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors.
    Hamada S; Suzuki T; Mino K; Koseki K; Oehme F; Flamme I; Ozasa H; Itoh Y; Ogasawara D; Komaarashi H; Kato A; Tsumoto H; Nakagawa H; Hasegawa M; Sasaki R; Mizukami T; Miyata N
    J Med Chem; 2010 Aug; 53(15):5629-38. PubMed ID: 20684604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a Highly Selective Cell-Active Inhibitor of the Histone Lysine Demethylases KDM2/7.
    Gerken PA; Wolstenhulme JR; Tumber A; Hatch SB; Zhang Y; Müller S; Chandler SA; Mair B; Li F; Nijman SMB; Konietzny R; Szommer T; Yapp C; Fedorov O; Benesch JLP; Vedadi M; Kessler BM; Kawamura A; Brennan PE; Smith MD
    Angew Chem Int Ed Engl; 2017 Dec; 56(49):15555-15559. PubMed ID: 28976073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unravelling KDM4 histone demethylase inhibitors for cancer therapy.
    Baby S; Gurukkala Valapil D; Shankaraiah N
    Drug Discov Today; 2021 Aug; 26(8):1841-1856. PubMed ID: 34051367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells.
    Berry WL; Janknecht R
    Cancer Res; 2013 May; 73(10):2936-42. PubMed ID: 23644528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases.
    Luo X; Liu Y; Kubicek S; Myllyharju J; Tumber A; Ng S; Che KH; Podoll J; Heightman TD; Oppermann U; Schreiber SL; Wang X
    J Am Chem Soc; 2011 Jun; 133(24):9451-6. PubMed ID: 21585201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.